Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade and Doxil in Relapsed Multiple Myeloma
NCT00706953Phase 2Withdrawn
- Sponsor
- Johnson & Johnson
- Start
- Jul 2008
- Primary completion
- Jun 2010
- Modality
- Modified Peptides, Targeted Liposomes, Stealth (PEGylated) Liposomes
01
Overview
A Phase 2 trial of bortezomib, pegylated liposomal doxorubicin in multiple myeloma (MM), sponsored by Johnson & Johnson. Planned start Jul 2008; status: withdrawn.
02
Drugs
bortezomibpegylated liposomal doxorubicin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00706953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00706953.